Home Stock

Stock Research: Kaken Pharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Kaken Pharmaceutical

TYO:4521 JP3207000005
40
  • Value
    80
  • Growth
    1
  • Safety
    Safety
    33
  • Combined
    23
  • Sentiment
    84
  • 360° View
    360° View
    40
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

KAKEN PHARMACEUTICAL CO., LTD. is a Japan-based company producing and selling pharmaceutical products. The company operates in the Pharmaceutical segment (manufacturing and sale of pharmaceuticals, medical devices, and agricultural drugs) and the Real Estate segment (leasing real estate). It is based in Japan. In the last fiscal year, the company had a market cap of $1133 million, profits of $390 million, revenue of $627 million, and 1126 employees.

more

ANALYSIS: With an Obermatt 360° View of 40 (better than 40% compared with alternatives), overall professional sentiment and financial characteristics for the stock Kaken Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Kaken Pharmaceutical. The consolidated Value Rank has an attractive rank of 80, which means that the share price of Kaken Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 80% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 84, which means that professional investors are more optimistic about the stock than for 84% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 1, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 33, meaning the company has a riskier financing structure than 67 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Growth
Weakest Rank Dividend Yield
Country Japan
Industry Pharmaceuticals
Size Medium
Website kaken.co.jp
Index
Kaken Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 19-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
80 48 84 75
Growth
1 63 5 35
Safety
Safety
33 84 94 96
Sentiment
84 20 12 8
360° View
360° View
40 58 42 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
19 28 22 7
Opinions Change
50 50 50 50
Pro Holdings
n/a 52 10 57
Market Pulse
92 22 16 7
Sentiment
84 20 12 8
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
80 48 84 75
Growth
1 63 5 35
Safety Safety
33 84 94 96
Combined
23 81 71 88
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
37 33 53 41
Price vs. Earnings (P/E)
8 24 60 86
Price vs. Book (P/B)
80 74 86 71
Dividend Yield
100 82 94 94
Value
80 48 84 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
1 1 11 11
Profit Growth
3 75 25 38
Capital Growth
9 61 35 48
Stock Returns
33 90 29 79
Growth
1 63 5 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
87 75 77 74
Refinancing
34 78 91 81
Liquidity
4 79 86 90
Safety Safety
33 84 94 96

Similar Stocks

Discover high‑ranked alternatives to Kaken Pharmaceutical and broaden your portfolio horizons.

Inpex

TYO:1605
Country: Japan
Industry: Oil & Gas Production
Size: X-Large
Full Stock Analysis

Daiwa House

TYO:1925
Country: Japan
Industry: Electric Utilities
Size: XX-Large
Full Stock Analysis

Kinden

TYO:1944
Country: Japan
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

NGK Insulators

TYO:5333
Country: Japan
Industry: Industrial Machinery
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

With good value and positive sentiment, but low growth and risky financing, this combination is generally dangerous as debt requires growth to sustain it. Only investors with a strong belief in future growth potential and a high-risk tolerance should consider this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews